MCID: MCL003
MIFTS: 40

Macular Holes

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Macular Holes

MalaCards integrated aliases for Macular Holes:

Name: Macular Holes 12 54 15 17 71
Macular Hole 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:7633
MeSH 43 D012167
NCIt 49 C34795
SNOMED-CT 67 232006002
UMLS 71 C0024441

Summaries for Macular Holes

MalaCards based summary : Macular Holes, also known as macular hole, is related to retinal detachment and retinal disease. An important gene associated with Macular Holes is TGFB2 (Transforming Growth Factor Beta 2), and among its related pathways/superpathways are AGE-RAGE signaling pathway in diabetic complications and Cell adhesion_Plasmin signaling. The drugs Ranibizumab and Verteporfin have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial.

Wikipedia : 74 A macular hole is a small break in the macula, located in the center of the eye's light-sensitive tissue... more...

Related Diseases for Macular Holes

Diseases related to Macular Holes via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 219)
# Related Disease Score Top Affiliating Genes
1 retinal detachment 32.1 VEGFA TGFB2 SERPINF1 RS1
2 retinal disease 32.1 RS1 RPE65 OPTC CRYAA
3 scotoma 31.5 VEGFA RPE65 KCNMA1
4 retinal vein occlusion 31.3 VEGFA SERPINF1 ANGPT2
5 microvascular complications of diabetes 5 31.2 VEGFA TGFB2 SERPINF1 CRYAA ANGPT2
6 microvascular complications of diabetes 1 31.2 VEGFA TGFB2 SERPINF1 ANGPT2
7 myopia 31.2 VEGFA TGFB2 SERPINF1 OPTC CRYAA
8 macular retinal edema 31.1 VEGFA SERPINF1 KCNMA1 CRYAA ANGPT2
9 uveitis 31.1 TGFB2 SERPINF1 CRYAA
10 endophthalmitis 31.0 VEGFA RPE65 CRYAA
11 intraocular pressure quantitative trait locus 30.5 VEGFA TGFB2 SERPINF1 CRYAA
12 vitreous syneresis 30.5 RS1 OPTC
13 kuhnt-junius degeneration 30.3 VEGFA FAM187A CRYAA ANGPT2
14 exudative vitreoretinopathy 1 30.2 VEGFA SERPINF1 CRYAA ANGPT2
15 retinal vascular disease 30.2 VEGFA SERPINF1 FN1 CRYAA ANGPT2
16 vitreoretinopathy, neovascular inflammatory 30.2 VEGFA TGFB2 RPE65 FN1 CRYAA ADM
17 branch retinal artery occlusion 30.1 VEGFA CRYAA
18 keratitis, hereditary 30.0 VEGFA MIF CRYAA
19 preretinal fibrosis 30.0 VEGFA TGFB2 FN1 ANGPT2
20 retinal vascular occlusion 29.9 VEGFA SERPINF1 KCNMA1 CRYAA
21 stargardt disease 29.9 RS1 RPE65 KCNMA1
22 vitreous detachment 29.9 VEGFA OPTC LHFPL5 KCNMA1 FN1 FAM187A
23 neovascular glaucoma 29.9 VEGFA TGFB2 RS1 CRYAA
24 melanoma, uveal 29.7 VEGFA TGFB2 MIR93 MIR9-1 CRYAA
25 central retinal artery occlusion 29.6 VEGFA CRYAA
26 open-angle glaucoma 29.5 TGFB2 OPTC CRYAA
27 eye disease 28.8 VEGFA TGFB2 SERPINF1 RS1 RPE65 MIR93
28 macular degeneration, age-related, 1 28.8 VEGFA TGFB2 SERPINF1 RS1 RPE65 OPTC
29 retinal perforation 28.3 VEGFA RS1 RPE65 OPTC FN1 DHDH
30 joint laxity, short stature, and myopia 11.0
31 cataract 10.8
32 retinoschisis 1, x-linked, juvenile 10.7
33 refractive error 10.7
34 vitreoretinopathy 10.6
35 neuroretinitis 10.6
36 microvascular complications of diabetes 2 10.6
37 retinitis 10.6
38 telangiectasis 10.5
39 retinitis pigmentosa 10.5
40 alport syndrome 10.4
41 47,xyy 10.4
42 lipodermatosclerosis 10.4 VEGFA ANGPT2
43 chorioretinitis 10.4
44 diabetic macular edema 10.4
45 coats disease 10.4
46 central retinal vein occlusion 10.4
47 eales disease 10.3 VEGFA SERPINF1
48 epithelioid cell melanoma 10.3 MIR93 MIR9-1 MIR374A
49 coloboma of macula 10.3
50 vitelliform macular dystrophy 10.3

Graphical network of the top 20 diseases related to Macular Holes:



Diseases related to Macular Holes

Symptoms & Phenotypes for Macular Holes

Drugs & Therapeutics for Macular Holes

Drugs for Macular Holes (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 87)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4 347396-82-1 459903
2
Verteporfin Approved, Investigational Phase 4 129497-78-5
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
6
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
7
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
8
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
9
Triazolam Approved, Investigational Phase 4 28911-01-5 5556
10
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
11
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
12
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
13
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
14
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
15
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
16 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
17
Ofloxacin Approved Phase 4 82419-36-1 4583
18
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
19 Angiogenesis Inhibitors Phase 4
20 Dermatologic Agents Phase 4
21 Photosensitizing Agents Phase 4
22 Anesthetics Phase 4
23 Hormones Phase 4
24 Antineoplastic Agents, Hormonal Phase 4
25 Ophthalmic Solutions Phase 4
26 Antiemetics Phase 4
27 Hormone Antagonists Phase 4
28 Gastrointestinal Agents Phase 4
29 glucocorticoids Phase 4
30 Anti-Inflammatory Agents Phase 4
31 Proxymetacaine Phase 4
32 Hypnotics and Sedatives Phase 4
33 BB 1101 Phase 4
34 Methylprednisolone Acetate Phase 4
35 Neuroprotective Agents Phase 4
36 Anti-Bacterial Agents Phase 4
37 Protective Agents Phase 4
38 Antibiotics, Antitubercular Phase 4
39
Nepafenac Approved, Investigational Phase 3 78281-72-8 151075
40
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
41
Diclofenac Approved, Vet_approved Phase 3 15307-86-5 3033
42
Dinoprostone Approved Phase 3 363-24-6 5280360
43
Bromfenac Approved Phase 3 91714-94-2 60726
44
Indomethacin Approved, Investigational Phase 3 53-86-1 3715
45
Lutein Approved, Investigational, Nutraceutical Phase 3 127-40-2 6433159
46 Pharmaceutical Solutions Phase 3
47 Fibrinolytic Agents Phase 3
48 Plasminogen Phase 3
49 Analgesics, Non-Narcotic Phase 3
50 Analgesics Phase 3

Interventional clinical trials:

(show top 50) (show all 140)
# Name Status NCT ID Phase Drugs
1 A Randomized, Comparative, Prospective Study of Anatomical Outcomes With Different Internal Limiting Membrane Peeling Area in Surgery for Idiopathic Macular Hole Completed NCT02930369 Phase 4
2 Impact of Different Fluidic Parameters on Development of Cystoid Macular Edema Following Phacoemulsification Completed NCT01385852 Phase 4
3 Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab Completed NCT02309281 Phase 4 aflibercept 2mg
4 A Randomized, Double-masked, Multicenter, Controlled Study of Effects of Internal Membrane Peeling Surgery in Patients With Idiopathic Macular Hole Measured by Optical Coherence Tomography. Recruiting NCT02905409 Phase 4
5 Cohort Study of the Clinical Course of Macular Diseases in Kagawa (Kagawa Macula Cohort Study) Recruiting NCT02321267 Phase 4 ranibizumab, aflibercept, pegaptanib, verteporphin
6 Comparative Analysis of Oral Sedation Versus Standard Intravenous Sedation in Vitreoretinal Surgery With Topical Anesthesia and Sub-tenon's Block Not yet recruiting NCT04346095 Phase 4 Oral Sedatives with or Without Analgesia;Intravenous Sedatives with or Without Analgesia
7 Intracanalicular Dexamethasone Insert for Management of Post-operative Pain and Inflammation in Patients Undergoing Vitreoretinal Surgery Not yet recruiting NCT04371445 Phase 4 Dexamethasone Ophthalmic Insert;Prednisolone Acetate 1% Oph Susp
8 A Randomized Study Comparing Brilliant Blue and Indocyanine Green as Intravitreal Dye in Macular Pucker and Macular Hole Unknown status NCT01083004 Phase 3
9 Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery Unknown status NCT01820520 Phase 3 brilliant blue G
10 Fingerprick Fresh Blood for Treatment of Chronic Corneal Ulcers, Persistent Epithelial Defects and Dry Eyes Unknown status NCT02153515 Phase 3
11 A Randomized, Sham-controlled, Double-masked, Multicenter Study Evaluating Ocriplasmin Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole Completed NCT01429441 Phase 3 Ocriplasmin
12 A Randomized, Placebo Controlled, Double-masked, Multicenter Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. Completed NCT00798317 Phase 3 Ocriplasmin 125µg;Placebo
13 A Phase III Study of A01016 125μg Intravitreal Injection in Subjects With Symptomatic Vitreomacular Adhesion - Comparison Study to Sham Injection Completed NCT01889251 Phase 3 Ocriplasmin;Sham injection
14 A Descriptive Study to Evaluate the Effectiveness of the Dye Compound of the Combination of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy Completed NCT01627977 Phase 3
15 Vitreous pge2 Level Changes After Topical Administration of Diclofenac 0.1%, Nepafenac 0.3%, Indomethacin 0.5% and Bromfenac 0.09% in Vitrectomy Patients Completed NCT03597867 Phase 3 Dicloftil;Nevanac;Indom;Yellox
16 Randomized Clinical Trial Assessing the Effects of Pneumatic Vitreolysis on Vitreomacular Traction Active, not recruiting NCT03647267 Phase 3
17 Analysis of Vitreous and Aqueous Humor for Ocular Growth Factors, Cytokines, Chemokines, and Ranibizumab Pharmacokinetics Associated With Various Retinal Disease Unknown status NCT02067013 Phase 2 Ranibizumab
18 Pars Plana Vitrectomy for Diabetic Fibrovascular Proliferation With and Without Internal Limiting Membrane Peeling Unknown status NCT00556244 Phase 1, Phase 2
19 Resolution of Vitreomacular Adhesion (VMA) Associated With Neovascular Age Related Macular Degeneration (AMD) With Intravitreal Microplasmin Unknown status NCT00996684 Phase 2 Microplasmin;Placebo control
20 A Dose-escalation Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy for Vitreomacular Traction Maculopathy Completed NCT00123279 Phase 2 Microplasmin
21 REVOLUTIONARY: REtinal Vein OccLUsion Treatment With Scatter Laser Guided by Ultra Widefield angIOgraphy in combiNAtion With Ranibizumab Study Phase II Completed NCT01247220 Phase 2 Ranibizumab
22 Single-Arm Study Assessing the Effects of Pneumatic Vitreolysis on Macular Hole Active, not recruiting NCT03677869 Phase 2
23 A Prospective, Multi-Center, Single-Dose, Phase 1 Clinical Trial Designed to Evaluate the Pharmacokinetics of Dexamethasone Phosphate Ophthalmic Solution Delivered Via the EyeGate® II Drug Delivery System in Patients Undergoing Vitrectomy for Macular Hole Repair or Epiretinal Membrane Peeling Completed NCT02644694 Phase 1 Dexamethasone Phosphate Ophthalmic Solution
24 The Intravitreal Autologous Platelet Concentrate Injection as an Adjunct of Vitrectomy for the Treatment of Refractory Macular Holes Unknown status NCT02081170
25 Surgical Inverted ILM Repositioning as Autologous Dressing for Idiopathic Full Thickness Macular Holes Treatment Unknown status NCT01228188
26 Macular Hole Surgery With and Without Internal Limiting Membrane Peeling:A Systematic Review and Meta-analysis Unknown status NCT01687829
27 A Single Center, Randomized and Controlled Clinical Study of Inverted Internal Limiting Membrane Insertion Combined With Air Tamponade in the Treatment of Macular Hole Retinal Detachment in High Myopia Unknown status NCT03383731
28 Dissociated Optic Nerve Fiber Layer Appearance and Retinal Sensitivity After Macular Hole Surgery With Temporal Inverted Internal Limiting Membrane Flap Technique Unknown status NCT03287102
29 Early Vitrectomy for Impending Macular Hole. Multicenter Clinical Trial Unknown status NCT01121965
30 Comparison of Postoperative Aqueous Flare After 20G Versus 23G Pars Plana Vitrectomy Unknown status NCT01969929
31 Early Vitrectomy for Macular Tractional Maculopathy. Multicenter Clinical Trial Unknown status NCT01121978
32 Intravitreous CytokinE Level in pAtient With retiNal Detachment Unknown status NCT03318588
33 Evaluation Use Optical Coherence Tomography - Rescan During Dissection of Macular Membranes : Pre and Post Operative Aspects Unknown status NCT02748421
34 Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel. Unknown status NCT00892619
35 A Multimodal Approach Towards an Objective Assessment of Macular Function at Retinal and Cortical Levels Unknown status NCT03517241
36 Vitreopapillary Traction and Optic Disc Morphology in Healthy Subjects, Vitreomacular Traction Patients and Glaucoma Patients Unknown status NCT02290795
37 Double Endotamponade With Perfluorodecalin and Silicone Oil in Retinal Detachment Surgery: Randomised Clinical Trial of Safety Unknown status NCT01959568
38 Outcome of Surgery for Idiopathic Macular Holes Completed NCT02895594
39 Preoperative Progression of Macular Holes Using Optical Coherence Tomography Completed NCT02203929
40 Membranepeeling With Brillant Blue Versus Membranepeeling With Indocyanine Green for Patients With Idiopathic Macular Holes. Completed NCT00757471
41 Long-term Outcome of Idiopathic Macular Hole Surgery Completed NCT00941291
42 A Randomized Clinical Trial of Face-down Protocol Versus Non-face-down Protocol After Surgery for Macular Holes. Completed NCT01974310
43 Fundus Autofluorescence Images in Gas-filled Eyes Immediately After Macular Hole Surgery Completed NCT02628262
44 Study of the Anatomic and Visual Outcomes in Patients With Initially Closed Macular Holes After Vitreoretinal Surgery Completed NCT01229657
45 The Application of M-charts and Microperimetry for the Assessment of Visual Function in Patients After Vitrectomy Due to the Full Thickness Macular Hole. Completed NCT03701542
46 Foveal Cone Outer Segment Resumption to Predict Visual Recovery After Macular Hole Surgery Completed NCT01381965
47 Correlation Between Visual Acuity and Recovery of Foveal Cone Microstructures After Macular Hole Surgery Completed NCT01306487
48 Human Amniotic Membrane Plug for Large Macular Holes Completed NCT03917602
49 Transposition of Internal Limiting Membrane in the Treatment of Macular Holes. A Descriptive Pilot Study Completed NCT02946372
50 Air Tamponade in Macular Holes < 400 μm Completed NCT02028481

Search NIH Clinical Center for Macular Holes

Genetic Tests for Macular Holes

Anatomical Context for Macular Holes

MalaCards organs/tissues related to Macular Holes:

40
Eye, Retina, Endothelial, Testes, Whole Blood, Cortex, Breast

Publications for Macular Holes

Articles related to Macular Holes:

(show top 50) (show all 4380)
# Title Authors PMID Year
1
Ratio of the vitreous vascular endothelial growth factor and pigment epithelial-derived factor in Eales disease. 61 54
20072643 2009
2
Differential expression of vitreous proteins in proliferative diabetic retinopathy. 54 61
16531280 2006
3
Angiopoietin concentrations in diabetic retinopathy. 61 54
15774928 2005
4
Elevated adrenomedullin in the vitreous of patients with diabetic retinopathy. 61 54
12566874 2003
5
Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. 61 54
12208245 2002
6
Macrophage migration inhibitory factor in ocular fluids of patients with uveitis. 61 54
11673308 2001
7
Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. 54 61
11264138 2001
8
Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative diabetic retinopathy. 61 54
10837392 2000
9
Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative vitreoretinopathy. 54 61
10612518 1999
10
Elevated adrenomedullin in the vitreous of patients with proliferative vitreoretinopathy. 61 54
10612519 1999
11
Comparison of recombinant transforming growth factor-beta-2 and placebo as an adjunctive agent for macular hole surgery. 54 61
9544645 1998
12
Surgical management of macular holes: results using gas tamponade alone, or in combination with autologous platelet concentrate, or transforming growth factor beta 2. 61 54
9497468 1997
13
[Surgical management of complete macular foramina]. 61 54
9081519 1996
14
Clinicopathologic correlation of an untreated macular hole and a macular hole treated by vitrectomy, transforming growth factor-beta 2, and gas tamponade. 54 61
8956640 1996
15
Closure of persistent macular holes with human recombinant transforming growth factor-beta 2. 61 54
8804755 1996
16
Vitrectomy, fluid-gas exchange and transforming growth factor--beta-2 for the treatment of traumatic macular holes. 54 61
9098285 1995
17
Progression of nuclear sclerosis and long-term visual results of vitrectomy with transforming growth factor beta-2 for macular holes. 54 61
7785710 1995
18
Progression of nuclear sclerosis and long-term visual results of vitrectomy with transforming growth factor beta-2 for macular holes. 54 61
7825689 1995
19
Idiopathic macular hole: a clinical review and current concepts in the diagnosis and management. 61 54
7852702 1994
20
Effects of intraocular bubble duration in the treatment of macular holes by vitrectomy and transforming growth factor-beta 2. 54 61
8035983 1994
21
Fluorescein angiographic characteristics of macular holes before and after vitrectomy with transforming growth factor beta-2. 61 54
8129001 1994
22
Full-thickness macular holes treated with vitrectomy and tissue glue. 61 54
7642336 1994
23
Retreatment of full-thickness macular holes persisting after prior vitrectomy. A pilot study. 61 54
8259275 1993
24
The effect of pars plana vitrectomy and transforming growth factor-beta 2 without epiretinal membrane peeling on full-thickness macular holes. 54 61
8510899 1993
25
Transforming growth factor-beta 2 significantly enhances the ability to flatten the rim of subretinal fluid surrounding macular holes. Preliminary anatomic results of a multicenter prospective randomized study. 61 54
8115729 1993
26
Transforming growth factor-beta 2 for the treatment of full-thickness macular holes. A prospective randomized study. 54 61
1495798 1992
27
FOVEA-SPARING VERSUS COMPLETE INTERNAL LIMITING MEMBRANE PEELING IN VITRECTOMY FOR THE TREATMENT OF MACULAR HOLES. 61
31274710 2020
28
INVERTED INTERNAL LIMITING MEMBRANE FLAP TECHNIQUES AND OUTER RETINAL LAYER STRUCTURES. 61
31259810 2020
29
PATIENT-REPORTED VISUAL FUNCTION FROM THE OCRIPLASMIN FOR TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION, INCLUDING MACULAR HOLE (OASIS) STUDY. 61
31259807 2020
30
EVALUATION OF ACCURACY AND UNIFORMITY OF THE NOMENCLATURE OF VITREORETINAL INTERFACE DISORDERS. 61
31180986 2020
31
Minimal internal limiting membrane peeling with ILM flap technique for idiopathic macular holes: a preliminary study. 61
32539696 2020
32
Spontaneous closure of small full-thickness macular holes: Presumed role of Müller cells. 61
31654489 2020
33
Surgical technique for approaching chronic or persistent macular holes: Two case reports. 61
32322749 2020
34
The new Myopic Traction Maculopathy Staging System. 61
32506945 2020
35
OCRIPLASMIN FOR VITREOMACULAR TRACTION IN CLINICAL PRACTICE: The INJECT Study. 61
32496343 2020
36
A customized posterior scleral reinforcement for myopic macular hole with retinal detachment and posterior staphyloma: A case report. 61
32508137 2020
37
Contributing ocular comorbidity to end-of-life visual acuity in medically treated glaucoma patients, ocular hypertension and glaucoma suspect patients. 61
32494040 2020
38
Novel use of Finesse Flex loop for macular hole retinal detachment. 61
32346652 2020
39
B-HEX pupil expander in vitreoretinal surgery - A case series. 61
32461476 2020
40
Central posterior lens capsule used instead of inverted ILM flap: a clinic-pathological case report. 61
32568960 2020
41
Posterior pole retinal tears following blunt ocular trauma. 61
32154440 2020
42
Spontaneous late reopening of a successfully operated and closed full-thickness macular hole. 61
32195442 2020
43
Vitrectomy for Idiopathic Macular Hole in Patients Aged 80 Years or Older: Efficacy and Safety. 61
31747306 2020
44
High-Throughput MicroRNA Profiling of Vitreoretinal Lymphoma: Vitreous and Serum MicroRNA Profiles Distinct from Uveitis. 61
32545709 2020
45
Two cases with retinitis pigmentosa that developed severe retinal atrophy long after vitreo-retinal surgery. 61
32420512 2020
46
Management of Full-Thickness Macular Hole in A Genetically Confirmed Case with Usher Syndrome. 61
32566994 2020
47
LAMELLAR MACULAR HOLES IN THE PRESENCE OF AGE-RELATED MACULAR DEGENERATION. 61
31145390 2020
48
Spontaneous closure of secondary eccentric macular holes following vitreoretinal surgery. 61
32541438 2020
49
Autosomal recessive bestrophinopathy with macular hole. 61
32461465 2020
50
Intraocular tumour necrosis factor ligand related molecule 1 A links disease progression of proliferative diabetic retinopathy after primary vitrectomy. 61
32064668 2020

Variations for Macular Holes

Expression for Macular Holes

Search GEO for disease gene expression data for Macular Holes.

Pathways for Macular Holes

Pathways related to Macular Holes according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.13 VEGFA TGFB2 FN1
2 10.49 VEGFA TGFB2 FN1

GO Terms for Macular Holes

Cellular components related to Macular Holes according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 VEGFA TGFB2 SERPINF1 RS1 PTGDS OPTC
2 extracellular space GO:0005615 9.36 VEGFA TGFB2 SERPINF1 RS1 PTGDS MIR93
3 platelet alpha granule lumen GO:0031093 9.33 VEGFA TGFB2 FN1

Biological processes related to Macular Holes according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 prostaglandin biosynthetic process GO:0001516 9.37 PTGDS MIF
2 negative regulation of gene expression GO:0010629 9.35 VEGFA TGFB2 SERPINF1 MIR93 MIF
3 response to wounding GO:0009611 9.33 TGFB2 FN1 ADM
4 protein homotrimerization GO:0070207 9.32 MIF ALOX5AP
5 neural retina development GO:0003407 9.26 TGFB2 RPE65
6 response to hypoxia GO:0001666 9.02 VEGFA TGFB2 KCNMA1 ANGPT2 ADM

Sources for Macular Holes

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....